Members from Venatorx will be attending the Symposium on Gram Negative Bacteria Resistance, hosted by The Wistar Institute. The symposium will focus on pathophysiology and prevention of Gram-negative bacteria. The goal is to bring together leading investigators in the field for in depth discussions on the current global state of infections that drive anti-microbial resistance (AMR). Perspectives to be covered include strategies to exploit novel bacterial vulnerabilities, updates on cutting-edge approaches towards Gram-negative infections and the next steps in combating AMR.

Dr. Lisa Wittmer, Chief Development Office at Venatorx Pharmaceuticals, will be participating in a public forum during which the U.S. Food and Drug Administration (FDA) will listen to comments on the draft guidance for industry, “Limited Population Pathway for Antibacterial and Antifungal Drugs,” that was published in the Federal Register on June 13, 2018. FDA is also reopening the comment period on this draft guidance for comments to be submitted for consideration before we finish work on the final version of the guidance.

Venatorx Pharmaceuticals will present ten posters featuring its two development-stage products, cefepime/VNRX-5133 and ceftibuten/VNRX-7145, at ASM Microbe 2019 to be held June 20-24 in San Francisco, CA. Venatorx will also present an overview if its antibacterial agents portfolio during the Pharma Pipeline Update, concentrating on its orally bioavailable beta-lactamase inhibitor, VNRX-7145, during the New Agents Discovery Summary Session.

President and CEO, Christopher J. Burns, Ph.D., will present on Monday, May 20, 2019 at 3:00pm at the Grand Hyatt New York.

Venatorx Pharmaceuticals will have 12 poster presentations at ECCMID 2019 featuring its Injectable and Orally Bioavailable Beta-Lactamase Inhibitor Drug Candidates, cefepime/VNRX-5133 and ceftibuten/VNRX-7145, respectively.

President and CEO, Christopher J. Burns, Ph.D., will present the Company's novel, orally-bioavailable beta-lactamase inhibitor, VNRX-7145, during the First Time Disclosure of Clinical Candidates at the American Chemical Society (ACS) National Meeting. The presentation entitled, “Discovery of VNRX-7145: A broad-spectrum orally bioavailable beta-lactamase inhibitor (BLI) for highly resistant bacterial infections (“superbugs”)” is scheduled for Wednesday, April 3, 2019 at 10:35am ET in the Valencia Ballroom A at the Orange County Convention Center in Orlando, FL.